Age-associated biomarker profiles of human breast cancer
- PMID: 12200028
- DOI: 10.1016/s1357-2725(02)00052-3
Age-associated biomarker profiles of human breast cancer
Abstract
To explore the hypothesis that aging not only increases breast cancer incidence but also alters breast cancer biology, we correlated patient age and diagnosis with tumor histology, stage and biomarkers independently determined from two different tumor archives: an American collection of approximately 800 paraffin-embedded and immunohistochemically analyzed primary breast cancers, and an European collection of approximately 3000 cryobanked primary breast cancers analyzed by ligand-binding and enzyme immunoassay (EIA). The prognostic biomarkers chosen for comparison represented surrogate measures of tumor: (i). proliferation, growth and genetic instability (mitotic and apoptotic indices, Ki-67/MIB-1-positivity, nuclear grade, p53-positivity), (ii). endocrine-dependence (estrogen receptor (ER), progesterone receptors (PR), pS2, Bcl2), (iii). growth factor receptor-dependence (ErbB2, EGFR/ErbB1), and (iv). angiogenic, invasive and proteolytic potential (uPA, PAI-1, Cathepsin D, VEGF). No biomarker reflecting tumor angiogenic, invasive or proteolytic potential showed a significant correlation with patient age at diagnosis. In contrast, significant inverse correlations (|r|>0.1; P< or =0.05) were observed for all measures of tumor growth and genetic instability as well as growth factor receptor overexpression (ErbB2 or EGFR positivity). Only one marker of endocrine-dependence, ER expression, showed a significant positive correlation with patient age at diagnosis. In summary, these findings support the hypothesis that breast cancer biology is significantly affected by patient age. In particular, breast tumors arising in older patients have slower growth rates, are more likely to be ER-positive, and are less likely to be p53-positive, EGFR-positive or ErbB2-positive.
Similar articles
-
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol. 2007 Nov 20;25(33):5287-312. doi: 10.1200/JCO.2007.14.2364. Epub 2007 Oct 22. J Clin Oncol. 2007. PMID: 17954709 Review.
-
Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast.Breast Cancer. 2002;9(2):118-26. doi: 10.1007/BF02967576. Breast Cancer. 2002. PMID: 12016391
-
Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.Oncology. 2001;60(1):72-80. doi: 10.1159/000055300. Oncology. 2001. PMID: 11150912
-
Can axillary dissection be avoided by improved molecular biological diagnosis?Acta Oncol. 2000;39(3):319-26. doi: 10.1080/028418600750013087. Acta Oncol. 2000. PMID: 10987228 Review.
-
[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].Geburtshilfe Frauenheilkd. 1996 Apr;56(4):177-83. doi: 10.1055/s-2007-1022256. Geburtshilfe Frauenheilkd. 1996. PMID: 8682282 German.
Cited by
-
Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2- breast cancer: a propensity score-matched retrospective cohort study using the SEER database.BMJ Open. 2024 Mar 15;14(3):e078782. doi: 10.1136/bmjopen-2023-078782. BMJ Open. 2024. PMID: 38490656 Free PMC article.
-
Using publicly available datasets to identify population-based transcriptomic landscape contributing to the aggressiveness of breast cancer in young women.Front Genet. 2023 Jan 4;13:1039037. doi: 10.3389/fgene.2022.1039037. eCollection 2022. Front Genet. 2023. PMID: 36685821 Free PMC article.
-
Overall survival analysis of > 65-year-old patients with breast cancer based on their molecular, clinicopathological and laboratory factors.Arch Med Sci. 2022 Apr 14;18(3):800-804. doi: 10.5114/aoms/147736. eCollection 2022. Arch Med Sci. 2022. PMID: 35591831 Free PMC article.
-
Differences in clinicopathologic features and subtype distribution of invasive breast cancer between elderly and non-elderly women.Fujita Med J. 2021;7(2):59-64. doi: 10.20407/fmj.2020-019. Epub 2020 Oct 10. Fujita Med J. 2021. PMID: 35111546 Free PMC article.
-
Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome.Cancers (Basel). 2021 Mar 19;13(6):1417. doi: 10.3390/cancers13061417. Cancers (Basel). 2021. PMID: 33808856 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous